Biodesix Reports Q3 Revenue Growth and Cuts 2026 Outlook
Third-quarter revenue rose 10% year over year to $24 million, below analyst expectations. Biodesix lowered its 2026 revenue outlook to $101 million–$103 million from $108 million–$114 million.
Biodesix reported total revenue of $24 million for the third quarter of 2026, representing a 10% increase year-over-year, though the results fell short of analyst expectations. The company's Diagnostic Testing revenue grew 16% to $23 million, supported by a 24% increase in test volumes, while Development Services revenue declined to $1 million. Biodesix reported a net loss of $8.0 million and an adjusted EBITDA loss of $3.9 million, both showing improvement over the prior-year period. Management revised the full-year 2026 revenue outlook to a range of $101 million to $103 million, down from previous guidance of $108 million to $114 million.
The company attributed the revised forecast to the timing of sales team expansion and the timing of Development Services contract execution and revenue recognition.